ORMP
Oramed Pharmaceuticals Inc (ORMP)
Healthcare • NASDAQ • $4.09+4.60%
- Symbol
- ORMP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.09
- Daily Change
- +4.60%
- Market Cap
- $165.42M
- Trailing P/E
- 2.73
- Forward P/E
- -51.13
- 52W High
- $4.22
- 52W Low
- $1.98
- Analyst Target
- $6.25
- Dividend Yield
- +6.13%
- Beta
- 1.26
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Company websiteResearch ORMP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.